Abstract: Objective The aim of this study was to investigate transarterial embolization (TAE) and hemangioma enucleation (HE) in the treatment of patients with hepatic hemangioma (HH). Methods 93 patients with HH were recruited in our hospital between March 2022 and March 2025, and TAE was conducted in 42 cases and HE was performed in another 51 cases. Pain at 24 hours post-surgery was assessed by using visual analog scale (VAS). Results Both TAE and HE were successfully completed in the two groups; operation time, intraoperative blood loss and hospital stay in TAE group were (59.7±14.8)min, (10.3±2.7)mL and (4.1±1.9)d,all significantly shorter or less than [(124.5±28.6)min, (472.5±53.9)mL and (9.5±1.8)d,respectively, P＜0.05] in HE group, while there was no significant difference as respect to VAS scores at 24 hours after operation [(4.2±1.3) vs. (4.7±1.5)] in the two groups (P＞0.05); by 72 hours after surgery, serum ALT and AST levels in HE group were (134.5±9.1)U/L and(91.2±8.4)U/L, both significantly higher than [(82.6±20.8)U/L and (63.1±11.6)U/L, respectively, P＜0.05] in TAE group; post-operationally, incidences of complications, such as cholangitis, infection and right upper quadrant pain, in the two groups(28.6% vs. 23.5%, P＞0.05) were not significantly different. Conclusion We believe that both TAE and HE could be performed in patients with HH, and clinicians should make choice based both HH status and technical proficiency.

Key words: Hepatic hemangioma, Transarterial embolization, Hemangioma enucleation, Therapy